Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210 Million
Myriad Genetics agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to Labcorp for $210 million, closing by early 2027.
Myriad Genetics agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to Labcorp for $210 million, closing by early 2027.
CMS says Medicare pays 16% more than private insurers for lab tests. Preliminary 2027 rates could save $1B a year, with cuts capped at 15%. Craig-Hallum flags code confusion at GeneDx, Adaptive and Myriad, but says the WGS drop looks overdone.
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.